Biotech Inducement Grants
Five biotechnology companies report new employee equity awards and stock inducement grants.
Anonymous
Key Points
1
Dianthus’s options have a 10-year term and an exercise price of $88.32 per share; vesting is 25% after one year, followed by equal monthly installments over the next 36 months.
2
Candel’s options carried an exercise price of $10.44 per share and were granted under the company’s 2025 Inducement Plan. The awards were approved September 30, 2026, and vest 25% after the employee’s first anniversary, then monthly over 36 months.
3
Adicet Bio’s option award had an exercise price of $7.14 per share, matching the stock’s Nasdaq closing price on September 30, 2026. It was granted under the company’s 2022 Inducement Plan, outside its stockholder-approved equity incentive plans.
4
Solid Biosciences’ 8,150 RSUs vest in four equal installments on each anniversary of the grant date, subject to the employee’s continued service, under its 2024 Inducement Stock Incentive Plan.
Five biotechnology companies announced equity grants for newly hired employees, using inducement awards to attract talent outside their regular stock plans. Financial Content reported that Dianthus Therapeutics granted options on 106,000 shares to six new hires, while Candel Therapeutics awarded options covering 85,900 shares to four employees. The awards carry exercise prices tied to recent stock prices and vest over four years with continued employment.
These inducement grants fall under Nasdaq Listing Rule 5635(c)(4), which allows companies to grant equity awards to new employees without shareholder approval. Yahoo Finance noted that Akebia Therapeutics, Adicet Bio, and Solid Biosciences also announced similar awards for individual hires. The grants typically feature 25% vesting after one year, then monthly installments over the remaining three years.
Dianthus and Candel Lead with Large Option Awards
Dianthus Therapeutics granted the largest package: options on 106,000 shares to six new employees. Financial Content reported the options have a 10-year term and an exercise price of $88.32 per share. Vesting follows the standard biotech model: 25% vests after one year, then equal monthly installments over 36 months. This structure locks in new talent over a multi-year horizon.
Candel Therapeutics awarded options on 85,900 shares to four hires with an exercise price of $10.44 per share. Financial Content stated these awards were granted under Candel's 2025 Inducement Plan and approved September 30, 2026. Like Dianthus, they follow a 25% cliff after one year, then monthly vesting over 36 months, tying employee retention to equity value.
Smaller Awards Target Individual High-Priority Hires
Three companies announced single-employee grants. Adicet Bio granted one new hire options on 725 shares with an exercise price of $7.14, matching the Nasdaq closing price on September 30, 2026. Yahoo Finance reported this award came under Adicet's 2022 Inducement Plan, bypassing shareholder-approved equity pools. Akebia Therapeutics awarded options on 8,400 shares to one employee.
Solid Biosciences took a different approach, awarding 8,150 restricted stock units (RSUs) instead of options to one new employee. Stock Titan explained that RSUs vest in four equal installments on each anniversary of the grant date, subject to the employee's continued service. The awards were granted under Solid's 2024 Inducement Stock Incentive Plan, offering a simpler vesting structure than traditional options.
Why Biotech Companies Use Inducement Awards
Inducement grants under Nasdaq Rule 5635(c)(4) give biotech firms flexibility in recruiting. The rule permits equity awards to new employees without shareholder approval, making hiring faster in a competitive talent market. Financial Content noted that companies use these grants to offer competitive packages while preserving their shareholder-approved equity pools for broader incentive programs.
The four-year vesting schedule aligns employee interests with company performance over time. All five companies structured grants with delayed vesting, discouraging short-term turnover. Stock Titan highlighted that this approach helps early-stage and clinical-stage biotech companies retain specialized talent—critical for drug development timelines that often span years.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
10
Articles
103
Reach
113
A
AnonymousAuthor
